Pyramid Analytics expands AI-driven Decision Intelligence with new OpenAI integration
20.3.2023 15:07:00 EET | Business Wire | Press release
Pyramid Analytics (Pyramid), a leading business analytics and decision intelligence provider, announced today at the Gartner Data & Analytics Summit in Orlando, Florida, that the Pyramid 2023 release extends its already category-leading, AI-driven augmented capabilities with the integration of GPT (generative pre-trained transformer) AI technology from OpenAI—the company behind ChatGPT and DALL-E 2—throughout the platform, interoperating with its deep set of current AI technologies.
The release harnesses the new GPT AI engines to drive complex logic, data science, and machine learning code generation; AI-driven storytelling capabilities; and even AI-assisted design templates and colors. The effort extends Pyramid’s broader vision to enable and drive adoption across the enterprise by empowering all users to solve data-centric business problems through no-code and AI-assisted analytics and decision intelligence.
Key facts about Pyramid’s OpenAI integration
OpenAI is integrated throughout the Decision Intelligence Platform—including the data preparation, data science, the business analytics and spreadsheet modules, and the storyboard and publication designer modules.
- In data preparation: OpenAI can be used to generate SQL, DAX, and MDX code automatically for complex data extraction queries.
- In data science: OpenAI can be used to generate Python and R code automatically to drive machine learning logic.
- In spreadsheets: OpenAI can be used to build spreadsheet formulas for users constructing business models.
- In storyboarding and publications: OpenAI can be used to generate designs for content and graphics.
Separately, OpenAI can be used with existing natural language querying (NLQ) engines to drive and enhance broader insights on enterprise-specific data, ultimately improving the existing tools for delivering automated storytelling and textual analysis.
Market recognition
Pyramid has long been recognized as an innovator in the decision intelligence and analytics space. The company’s Decision Intelligence Platform was ranked #1 —by leading analyst firm Gartner—for “Augmented Analytics” in the 2022 Gartner Analytics and Business Intelligence (ABI) Critical Capabilities report.
Other leading analysts—such as 451 Research , Ventana Research , Dresner Advisory Services , and BARC —recognize Pyramid for its platform-based approach to no-code capabilities and AI/augmented analytics to enable all user types to drive sophisticated analytics easily. Critically, Pyramid’s existing augmented capabilities (NLQ, Chatbot, Smart Insights, Smart Model, Auto Discovery, Fill in the Blanks, Explain, etc.) uniquely operate directly on enterprise data without data duplication, custom models, proprietary data layers, or specialized data treatments.
Demos
Click here to schedule a demo of the Pyramid Decision Intelligence Platform and to learn more about OpenAI on the platform.
Quotes
Avi Perez, CTO and Co-Founder, Pyramid Analytics : “By integrating OpenAI throughout the Pyramid Decision Intelligence Platform, we are extending our existing AI and augmented capabilities with the latest generative AI tech, transforming—and simplifying—the decision-making experience further. As a no-code/low-code platform, Pyramid is designed to extend advanced analytics—from descriptive to predictive to prescriptive—for non-technical businesspeople, allowing them to make informed decisions that drive business outcomes.”
Omri Kohl, CEO and Co-Founder, Pyramid Analytics: “At Pyramid, we believe the key to widespread adoption of data analytics requires an analytics experience that meets different people’s needs, regardless of their technical skills or analytics aptitude. By strategically integrating generative AI technologies like OpenAI, we are taking our AI vision to the next level.”
About Pyramid Analytics
Pyramid Analytics is the next generation of decision intelligence. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Platform operates directly on any data, enabling governed self-service for any person; and meeting analytical needs in a no-code environment without data extraction, ingestion, and duplication. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo today.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not hinder talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005287/en/
Contact information
Pyramid Analytics
Pete Vomocil
SVP, Global Marketing, Pyramid Analytics
pr@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom